Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples.

Santos MFM, Oliveira FCAC, Kishimoto RK, Borri D, Santos FPS, Campregher PV, Silveira PAA, Hamerschlak N, Mangueira CLP, Duarte FB, Crepaldi AH, Salvino MA, Velloso EDRP.

Braz J Med Biol Res. 2019 Feb 14;52(2):e8194. doi: 10.1590/1414-431X20188194.

2.

ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study.

Correia RP, Matos E Silva FA, Bacal NS, Campregher PV, Hamerschlak N, Amarante-Mendes GP.

Hematol Transfus Cell Ther. 2018 Oct-Dec;40(4):317-325. doi: 10.1016/j.htct.2018.03.008. Epub 2018 Jun 11.

3.

Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.

Datoguia TS, Velloso EDRP, Helman R, Musacchio JG, Salvino MA, Soares RA, Higashi M, Fadel AV, E Silva RSA, Hamerschlak N, Santos FPS, Campregher PV.

Med Oncol. 2018 Sep 5;35(11):141. doi: 10.1007/s12032-018-1179-3.

PMID:
30187210
4.

Ferritin light chain gene mutations in two Brazilian families with hereditary hyperferritinemia-cataract syndrome.

Petroni RC, Rosa SEAD, Carvalho FP, Santana RAF, Hyppolito JE, Nascimento CMDB, Hamerschlak N, Campregher PV.

Einstein (Sao Paulo). 2017 Oct-Dec;15(4):492-495. doi: 10.1590/S1679-45082017RC4006. Epub 2017 Jul 24. English, Portuguese.

5.

Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.

Campregher PV, Mattos VRP, Salvino MA, Santos FPS, Hamerschlak N.

Einstein (Sao Paulo). 2017 Jul-Sep;15(3):355-358. doi: 10.1590/S1679-45082017RC3784. Epub 2017 Jul 24. English, Portuguese.

6.

Therapeutic salivary monitoring of IV busulfan in patients undergoing hematopoietic stem cell transplantation: a pilot study.

Bezinelli LM, Eduardo FP, de Carvalho DLC, Dos Santos Ferreira CE, de Almeida EV, Sanches LR, Esteves I, Campregher PV, Hamerschlak N, Corrêa L.

Bone Marrow Transplant. 2017 Oct;52(10):1384-1389. doi: 10.1038/bmt.2017.142. Epub 2017 Jul 24.

PMID:
28737776
7.

Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.

Campregher PV, Halley NDS, Vieira GA, Fernandes JF, Velloso EDRP, Ali S, Mughal T, Miller V, Mangueira CLP, Odone V, Hamerschlak N.

Leuk Lymphoma. 2017 Dec;58(12):2969-2972. doi: 10.1080/10428194.2017.1318437. Epub 2017 May 16. No abstract available.

PMID:
28509585
8.

A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia.

Campregher PV, Petroni RC, Muto NH, Sitnik R, de Carvalho FP, Bacal NS, Velloso ED, Oliveira GB, Pinho JR, Torres DC, Mansur MB, Hassan R, Lorand-Metze IG, Chiattone CS, Hamerschlak N, Mangueira CL.

Biomed Res Int. 2016;2016:4247908. doi: 10.1155/2016/4247908. Epub 2016 Dec 15.

9.

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.

Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V.

J Thorac Oncol. 2017 Mar;12(3):446-457. doi: 10.1016/j.jtho.2016.11.2224. Epub 2016 Nov 27.

10.

Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm.

Helman R, Pereira WO, Marti LC, Campregher PV, Puga RD, Hamerschlak N, Chiattone CS, Santos FPS.

Br J Haematol. 2018 Feb;180(3):443-445. doi: 10.1111/bjh.14327. Epub 2016 Sep 21. No abstract available.

PMID:
27650062
11.

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation.

Perini GF, Campregher PV, Ross JS, Ali S, Hamerschlak N, Santos FP.

Blood Cancer J. 2016 May 13;6:e420. doi: 10.1038/bcj.2016.25. No abstract available.

12.

A novel mechanism of NPM1 cytoplasmic localization in acute myeloid leukemia: the recurrent gene fusion NPM1-HAUS1.

Campregher PV, de Oliveira Pereira W, Lisboa B, Puga R, Deolinda ER, Helman R, Marti LC, Guerra JC, Manola KN, Petroni RC, Bezerra AM, Costa FF, Hamerschlak N, de Souza Santos FP.

Haematologica. 2016 Jul;101(7):e287-90. doi: 10.3324/haematol.2015.137364. Epub 2016 Apr 1. No abstract available.

13.

Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis.

Monte-Mor Bda C, Ayres-Silva Jde P, Correia WD, Coelho AC, Solza C, Daumas AH, Bonamino MH, Santos FP, Datoguia TS, Pereira Wde O, Lisboa BC, Ramos CF, Machado-Neto JA, Hamerschlak N, Campregher PV, Traina F, Pagnano KB, Zalcberg I.

Blood Cells Mol Dis. 2016 Sep;60:74-7. doi: 10.1016/j.bcmd.2016.03.003. Epub 2016 Mar 8. No abstract available.

PMID:
26994960
14.

Immunophenotypic evolution of blast populations in pediatric acute myeloid leukemia.

Pereira WO, Correia RP, Hamerschlak N, Bacal NS, Campregher PV.

Einstein (Sao Paulo). 2016 Mar 8;14(2):288-9. doi: 10.1590/S1679-45082016AI3516. English, Portuguese. No abstract available.

15.

Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis.

Campregher PV, Pereira WO, Lisboa B, Puga R, Helman R, Miyagi M, da Mata EH, Datoguia TS, Velloso ED, Bacal NS, Ross JS, Ali S, Miller V, Costa FF, Hamerschlak N, Santos FP.

Mol Cancer. 2015 Nov 19;14:197. doi: 10.1186/s12943-015-0471-5.

16.

The role of magnetic resonance imaging-T2* in the evaluation of iron overload early in hereditary hemochromatosis. A cross-sectional study with 159 patients.

Assis RA, Kay FU, Conti FM, Campregher PV, Szarf G, Diniz MS, Rodrigues M, Helman R, Funari MB, Wood J, Hamerschlak N.

Am J Hematol. 2015 Dec;90(12):E220-1. doi: 10.1002/ajh.24189. Epub 2015 Nov 17. No abstract available.

17.

Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease.

e Moura de Souza CL, Bub CB, Torres MA, Velloso ED, Silveira PA, Correia RP, Bacal NS, Mangueira CL, Fernandes JF, Odone Filho V, Hamerschlak N, Campregher PV.

J Clin Pathol. 2015 Nov;68(11):950-2. doi: 10.1136/jclinpath-2015-203013. Epub 2015 Jul 20. No abstract available.

PMID:
26193901
18.

Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.

Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, Miles CR.

Blood Cancer J. 2015 Feb 6;5:e278. doi: 10.1038/bcj.2014.95. No abstract available.

19.

Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.

Campregher PV, Hamerschlak N, Colturato VA, Mauad MA, de Souza MP, Bouzas LF, Tavares Rde C, Barros JC, Chiattone R, Paz A, Silla L, Vigorito AC, Miranda E, Funke VA, Flowers ME.

Eur J Haematol. 2015 Nov;95(5):421-5. doi: 10.1111/ejh.12508. Epub 2015 Feb 19.

PMID:
25645430
20.

Does angiogenesis matter in primary myelofibrosis?

Campregher PV.

Rev Bras Hematol Hemoter. 2014 Sep-Oct;36(5):311-2. doi: 10.1016/j.bjhh.2014.07.009. Epub 2014 Jul 17. No abstract available.

21.

Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.

Correia RP, Silva FA, Bacal NS, Campregher PV, Hamerschlak N, Amarante-Mendes GP.

Rev Bras Hematol Hemoter. 2014 Jan-Feb;36(1):60-4. doi: 10.5581/1516-8484.20140015. Epub 2014 Mar 12. Review. Portuguese. No abstract available.

22.

Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.

Correia RP, Matos E Silva FA, Bacal NS, Campregher PV, Hamerschlak N, Amarante-Mendes GP.

Rev Bras Hematol Hemoter. 2014;36(1):60-4. doi: 10.5581/1516-8484.20140015. Review.

23.

Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.

Campregher PV, Hamerschlak N.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):271-6. doi: 10.1016/j.clml.2013.12.016. Epub 2013 Dec 30. Review.

PMID:
24548608
24.

Metastatic melanoma mimicking acute leukaemia.

Kaliks RA, Silveira PA, Osawa A, Campregher PV, Bacal NS, Velloso ED.

Br J Haematol. 2014 Apr;165(1):1. doi: 10.1111/bjh.12669. Epub 2013 Nov 25. No abstract available.

PMID:
24266414
25.

Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy.

Pereira WO, Bacal NS, Correia RP, Kanayama RH, Veloso ED, Borri D, Hamerschlak N, Campregher PV.

BMC Res Notes. 2013 Oct 29;6:433. doi: 10.1186/1756-0500-6-433.

26.

Primary central nervous system lymphoma: what a neurologist/neurosurgeon should know?

Perini GF, Campregher PV, Santos FP, Hamerschlak N.

Arq Neuropsiquiatr. 2013 Apr;71(4):254-7. Review.

27.

The detection of KIT mutations in acute myeloid leukemia.

Machado LE, Pinho JR, Sitnik R, Muto NH, Velloso ED, Petroni RC, Campregher PV.

Einstein (Sao Paulo). 2012 Jul-Sep;10(3):286-91. English, Portuguese.

28.

Molecular biology of Philadelphia-negative myeloproliferative neoplasms.

Campregher PV, Santos FP, Perini GF, Hamerschlak N.

Rev Bras Hematol Hemoter. 2012;34(2):150-5. doi: 10.5581/1516-8484.20120035.

29.

Overlap and effective size of the human CD8+ T cell receptor repertoire.

Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, Carlson CS, Warren EH.

Sci Transl Med. 2010 Sep 1;2(47):47ra64. doi: 10.1126/scitranslmed.3001442.

30.

Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, Vigorito A, Campregher PV, Martin PJ, Flowers ME, Chien JW.

Biol Blood Marrow Transplant. 2010 Jan;16(1):53-61. doi: 10.1016/j.bbmt.2009.08.016. Epub 2009 Oct 17.

31.

Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.

Campregher PV, Srivastava SK, Deeg HJ, Robins HS, Warren EH.

Exp Hematol. 2010 Mar;38(3):202-12. doi: 10.1016/j.exphem.2009.12.004. Epub 2009 Dec 24.

32.

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS.

Blood. 2009 Nov 5;114(19):4099-107. doi: 10.1182/blood-2009-04-217604. Epub 2009 Aug 25.

33.

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.

Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, Fero ML, Warren EH, Lee SJ, Appelbaum FR, Martin PJ, Flowers ME; National Institutes of Health.

Blood. 2009 Jul 16;114(3):702-8. doi: 10.1182/blood-2009-03-208983. Epub 2009 May 21.

34.

Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.

Flowers ME, Storer B, Carpenter P, Rezvani AR, Vigorito AC, Campregher PV, Moravec C, Kiem HP, Fero M, Georges G, Warren E, Lee S, Sanders JE, Appelbaum F, Martin PJ.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1380-4. doi: 10.1016/j.bbmt.2008.09.017.

35.

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.

Campregher PV, Gooley T, Scott BL, Moravec C, Sandmaier B, Martin PJ, Deeg HJ, Warren EH, Flowers ME.

Bone Marrow Transplant. 2007 Nov;40(10):965-71. Epub 2007 Sep 10.

PMID:
17846603

Supplemental Content

Loading ...
Support Center